X
ARQT icon

Xponance’s Arcutis Biotherapeutics ARQT Stock Holding History

Xponance’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
11,287
+202
+2% +$4.71K ﹤0.01% 1411
2026
Q1 		$261K Buy
11,085
+1,687
+18% +$43.1K ﹤0.01% 1352
2025
Q4 		$273K Buy
+9,398
New +$241K ﹤0.01% 1229

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Xponance's ARQT Position: Q2 2026 in Review

Xponance increased its Arcutis Biotherapeutics (ARQT) stake by 1.8% in Q2 2026, buying an estimated $4.71K and bringing the position to 11,287 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Xponance first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Xponance held 11,287 shares of Arcutis Biotherapeutics worth $296K as of Q2 2026.
  • Xponance bought 202 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.71K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1411 holding.
  • Xponance first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.